NEW YORK (Reuters Health) - Even with the use of drug-eluting stents, restenosis is still a problem, Dr. Hyo-Soo Kim, at the National University Hospital in Seoul, and associates note in their paper in the August 18th issue of The Lancet. The researchers hypothesized that the COX-2 inhibitor celecoxib, which has anti-inflammatory, antiproliferative and pro-apoptotic effects, would decrease the rate of restenosis.
